Nice University Hospital
Nice, 06000, France
Location status: Recruiting
NCT Number: NCT05776511
Eye movement is a complex neurological function controlled by many structures located in the central nervous system. The eyeball is mobile within the orbit and its movements are carried out using 6 muscles innervated by 3 oculomotor nerves allowing to perform reflex or voluntary eye movements in all elementary directions.
So-called internuclear structures allow the two eyeballs to perform combined movements. The attack of these structures during an acute or chronic neurological disease will most often cause oculomotor paralysis in one or more directions of gaze which will be perceived by the patient as double vision.
So-called supranuclear structures make it possible to generate different types of eye movements: saccades, which are extremely rapid eye movements of very short duration, eye pursuit, which is a slow movement whose purpose is to follow a moving visual target and finally, certain neural circuits are intended to stabilize the gaze.
Many neurological diseases can be accompanied by oculomotor abnormalities affecting saccades or ocular pursuit. These include neurodegenerative diseases characterized by diffuse neurological damage.
Involvement of gaze stabilization structures is also frequently found in certain neurological diseases affecting the posterior fossa.
The clinical examination of oculomotricity focuses mainly on the analysis of ocular mobility in the different directions of space by asking the subject to fix an object (for example a pen) or the index of the examiner in moving in different directions in space. During a classic clinical examination, it is then possible to detect anomalies such as oculomotor paralysis or nystagmus, it is however very difficult to assess the speed or the precision of the saccades, as well as the quality of the pursuit ocular.
As a result, the development of techniques to accurately record eye movements has emerged as a need in order to help in the diagnosis of certain visual disorders and certain neurodegenerative diseases.
Video oculography (VOG) is a technique for precisely recording and analyzing the movements of the eyeballs.
The use of VOG in neurology has long been dominated by helping to diagnose certain neurodegenerative diseases and in particular certain atypical Parkinson's syndromes. The value of VOG has also been demonstrated in certain pathologies characterized by atrophy of the brainstem or cerebellum, of hereditary or acquired origin. Some studies have also assessed its contribution to the diagnosis and management of certain dementias and certain psychiatric diseases such as schizophrenia. More recently, the interest of VOG has also emerged in the management of patients with a demyelinating disease of the multiple sclerosis spectrum.
The VOG has a number of limitations to its large-scale use, first of all, it is an examination requiring specific, relatively expensive equipment. On the other hand, the examination requires know-how, both for the passing of the tests but also for the processing and analysis of the data.
The eVOG (mobile VideoOculoGraphy) application has been developed to record oculomotor movements during different paradigms: horizontal saccades, vertical saccades, antisaccades, horizontal pursuit, vertical pursuit thanks to a tablet fixed on a support allowing keep in a stable and fixed position.
The eVOG app was compared to a conventional VOG platform in a first study. The objective was to compare the measurements obtained by the eVOG application to the measurements collected by the standard method in a sample of patients with multiple sclerosis. This study showed that the detection of different anomalies by eVOG is correlated with classic VOG.
In view of these encouraging preliminary results, a prospective study could be set up with the objective of evaluating the value of digital VOG in the diagnostic process in patients referred to a tertiary center for white matter signal abnormalities on MRI.
the hypothesis is that subclinical oculomotor disorders will be found more frequently in the group of patients with MS spectrum disease due to the presence in this pathology of diffuse inflammatory and degenerative damage to brain tissue, unlike the others inflammatory or non-inflammatory pathologies.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Nice, 06000, France
Location status: Recruiting
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Patients Inclusion Criteria:
controls Inclusion criteria:
Exclusion criteria
video digital oculography
Time frame: day of inclusion
The interpretation of the VOG will reveal the presence or absence of the following eye movement abnormalities (EMA):
Time frame: day of inclusion
The interpretation of the VOG will reveal the presence or absence of the following eye movement abnormalities (EMA):
Time frame: day of inclusion
The interpretation of the VOG will reveal the presence or absence of the following eye movement abnormalities (EMA):
Time frame: day of inclusion
The interpretation of the VOG will reveal the presence or absence of the following eye movement abnormalities (EMA):
Time frame: day of inclusion
The interpretation of the VOG will reveal the presence or absence of the following eye movement abnormalities (EMA):
Time frame: day of inclusion
score (0 to 5) of he interpretation of the VOG will reveal the presence or absence of the following eye movement abnormalities (EMA)
Time frame: day of inclusion
Global and regional volumetric measurements
Time frame: each year to 2 years
EDSS score
Time frame: at year 1 and year 2
Evolution towards an active form requiring the use of a second-line treatment (natalizumab, ocrelizumab, fingolimod, cladribine)
Time frame: at year 1 and year 2
Evolution towards a secondary progressive form (clinically)
Time frame: day of inclusion
type of EMA
Time frame: day of inclusion
Number of EMA
Contact information is provided by the study sponsor or research team.
Cassandre LANDES CHATEAU
CONTACT
Mikael COHEN
CONTACT
Centre Hospitalier Universitaire de Nice
Other
Diagnostic Value of Digital Video Oculography in Patients With White Matter Lesions
Acronym: DIVEyes
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06280755
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Prague, Praha 2, Czechia
View Trial DetailsNCT05204459
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Los Angeles, California, United States
View Trial DetailsNCT05388331
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Nice, France
View Trial DetailsNCT07636876
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Genova, Italy
View Trial Details